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Immunosuppressive treatment and progression of histologic
lesions in kidney allografts. Renal transplantation is the best
therapeutic option for patients with end-stage renal disease.
Although short-term results are excellent, long-term graft sur-
vival has not improved substantially in recent times. Chronic
allograft nephropathy (CAN) and death with a functioning
graft are the most important causes of graft loss. Recent evi-
dence shows that nephrotoxicity of calcineurin inhibitors con-
tributes to CAN, and the introduction of non-nephrotoxic
drugs such as mycophenolate mofetil (MMF) and mammalian
target of rapamycin inhibitors may provide new immunosup-
pressive strategies to improve long-term results after renal
transplantation. MMF decreases the risk of developing chronic
allograft failure and is useful for treating established CAN, be-
cause it has a beneficial effect on allograft fibrosis. Treatment
with sirolimus (SRL), a basic immunosuppressive drug given in
association with MMF, may offer better renal function, decrease
the prevalence of CAN, and downregulate expression of genes
responsible for the progression of CAN than treatment with cy-
closporine A (CsA). SRL also permits an early elimination of
CsA from SRL-CsA-steroid regimens and shows better renal
function and improved renal histology without risk of rejec-
tion. Notably, this approach improves graft survival at 4 years.
Further multicenter studies are needed to determine whether
both approaches produce similar results by comparing immuno-
suppression caused by SRL-based and tacrolimus (TAC)-based
treatments. Because TAC is the most commonly used antical-
cineurin drug, it is important to compare the effects of steroid-
TAC-SRL treatment with and without elimination of TAC.
Finally, although caution is needed, the use of non-nephrotoxic
immunosuppressive treatment may change the natural history
of CAN.
Renal transplantation is the therapy of choice for pa-
tients with end-stage renal disease [1]. The short-term
outcome of renal transplantation has improved dramat-
ically in the past 20 years. Introduction of cyclosporine
(CsA) and newer, more efficient immunosuppressive
drugs such as tacrolimus (TAC), mycophenolate mofetil
(MMF), and rapamycin (sirolimus [SRL]) has reduced
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the prevalence of acute rejection and increased the rate
of graft survival from 90% to 95% at 1 year in most units
[2]. However, long-term graft survival has not improved
substantially [3]. The most important causes of late al-
lograft failure are chronic allograft nephropathy (CAN),
death of the functioning graft, and de novo or recurrent
disease [4]. Chronic CsA-TAC nephrotoxicity can con-
tribute to CAN, which is the second most common cause
of graft loss (after death with a functioning graft) [5].
CAN is characterized by progressive renal dysfunction
accompanied by interstitial fibrosis, tubular atrophy, vas-
cular occlusive changes, and glomerulosclerosis [6]. De-
spite the use of potent immunosuppressive combinations,
biopsies show that the rate of CAN may be as high as
94% in the first year [7]. The long-term presence of an-
ticalcineurin nephrotoxicity is almost universal [7]. The
introduction of MMF and target of rapamycin (TOR) in-
hibitors, a new class of antirejection dugs, may provide
new immunosuppressive strategies to prevent, decrease,
or slow the progression of graft failure.
In this review, we discuss the most important recent
data about the effects of non-nephrotoxic immunosup-
pression in the treatment of chronic renal dysfunction
and focus particularly on the progression of histological
lesions in kidney allografts.
CAN IN PATIENTS RECEIVING CsA OR TAC
Histopathologic results of 2-year protocol biopsies
from 144 patients enrolled in the United States FK506
kidney study showed that acute rejection occurred in 9%
of patients treated with TAC and 9.2% of patients treated
with CsA. CAN was also similar with the two treatments
(73.2% and 62%, respectively), showing that nephrotoxi-
city and acute rejection are the most significant predictors
of CAN. The authors concluded that non-immunologic
factors, such as CsA or TAC nephrotoxicity, may play an
important role in CAN [8].
Taking protocol biopsies regularly after transplanta-
tion, Nankiwell et al evaluated the natural history of
CAN in a prospective study of 120 recipients of pancreas–
kidney transplantation [7]. They described two distinct
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phases of injury. The initial phase of early tubulointersti-
tial lesion arises because of ischemic injury, prior severe
rejection, and a subclinical rejection showing that grade I
CAN was present in 94.2% of patients. Notably, the com-
bination TAC plus MMF eliminated subclinical rejection
and reduced tubulointerstitial damage at 12 months [9].
Compared with TAC, CsA increases chronic interstitial
fibrosis, and MMF is more protective than azathioprine
(Aza), independent of their nephrotoxic and immuno-
logic properties [10]. The later phase of CAN occurs after
1 year and is characterized by microvascular and glomeru-
lar injury. The presence of CsA and TAC nephrotoxicity
(e.g., arterial hyalinosis, ischemic glomerulosclerosis, and
tubulointerstitial damage) implicated in the late perma-
nent injury approaches 100% at 10 years. Severe CAN is
present in 58.4% of patients at 10 years [6]. This study
clearly demonstrated the contribution of nephrotoxicity
by anticalcineurin drugs in the development and progres-
sion of CAN.
Recent studies have compared the effect of antical-
cineurin drugs on the development of CAN. Moreso et al
[11] performed a case-control study to compare histologi-
cal lesions in protocol biopsies from patients treated with
TAC + MMF with those treated with CsA + MMF. Pro-
tocol biopsies were performed 4 to 6 months after trans-
plantation. Although subclinical acute rejection occurred
less frequently in TAC patients (14.2% vs. 34.7%), the to-
tal chronic score and the prevalence of CAN did not differ
between groups (38.8% in CsA and 34.6% in TAC). Ju-
rewicz [12], Murphy et al [13], and Baboolal et al [14] used
randomized trials to compare treatment with CsA mi-
croemulsion and TAC, and reported that treatment with
CsA was associated with an increased allograft fibrosis.
Baboolal et al also suggest that the development of allo-
graft fibrosis is mediated by an upregulation of profibrotic
growth factors [14].
NON-NEPHROTOXIC IMMUNOSUPPRESSION IN
THE TREATMENT AND PROGRESSION OF
HISTOLOGICAL LESIONS IN KIDNEY
ALLOGRAFTS
Azathioprine
A recent article described an extended follow-up of
an open-label, randomized trial that examined conver-
sion to Aza as early as 3 months after transplantation.
One hundred twenty-eight patients were enrolled in a
single center in 1983 and randomly assigned to continue
CsA therapy (N = 68) or were converted to Aza (N =
60). At 15 years, graft survival tended to be lower in the
CsA group (64% vs. 76.5%). The relative risk (RR) of
CAN was significantly higher in patients receiving CsA
(RR, 4.3; 95% confidence interval, 1.4–12.9), and the in-
cidence of CAN was lower in patients with Aza (28% vs.
62%). These findings suggest a role of CsA nephrotoxi-
city in the development of CAN in a study started more
than 20 years ago. The authors recommended the same
immunosuppressive strategy using MMF instead of Aza
[15].
MYCOPHENOLATE MOFETIL
MMF, the morpholinoethyl ester of mycophenolic acid,
inhibits purine metabolism by inhibiting the enzyme in-
osine monophosphate dehydrogenase. MMF inhibits the
proliferation of T and B cells and the synthesis of anti-
bodies by B cells [16]. MMF administration in associa-
tion with steroids, CsA, or TAC reduces acute rejection
[17, 18]. Notably, MMF is not nephrotoxic and does not
have any hypertensive effect [17, 18]. The Federal Drug
Administration approved its use in renal transplantation
in 1995. Currently, nearly 80% of patients receive MMF
in various immunosuppressive combinations after renal
transplantation in the United States [19].
Ojo et al analyzed 66,774 renal transplant recipients
from the US renal transplant registry and showed that
MMF decreased the RR of developing CAN by 27% (RR,
0.73) [20]. Notably, this effect was independent of acute
rejection, suggesting that, through its antiproliferative
effects, MMF could be useful in protecting against vas-
cular damage. In animal models of chronic allograft arte-
riolopathy, MMF decreases vascular intimal hyperplasia
and the development of lesions similar to that seen in pa-
tients with CAN. Censored graft survival with MMF was
significantly better than that with Aza at 4 years (85.6%
vs. 81.9%). The most relevant conclusion of this impor-
tant study is that MMF decreases the risk of developing
chronic allograft failure. Reporting for the Tricontinental
Mycophenolate Mofetil Renal Transplant Study Group,
Mathew compared 3-year graft survival in two groups of
renal transplant patients receiving MMF (1 g or 2 g) or
Aza in association with CsA and steroids, and found sig-
nificantly higher graft survival in the MMF group [21].
The Spanish Cooperative Study Group of Chronic Al-
lograft Nephropathy prospectively explored the poten-
tial therapeutic role of MMF in patients diagnosed with
CAN [22]. One hundred-twenty patients with biopsy-
proven CAN on double or triple therapy with CsA were
treated with MMF. Before the introduction of MMF, pa-
tients showed progressive deterioration of renal function
(glomerular filtration rate [GFR] 54.8 mL/min vs. 39.7
mL/min). After MMF started, renal function remained
stable (GFR 39.7 mL/min vs. 41.3 mL/min) with a sig-
nificant change in the slope of the GFR from −0.0144
to +0.00045. This positive reduction in the slope of the
GFR was also seen in patients in whom CsA blood lev-
els remained unchanged during follow-up. More recently,
Dudley et al demonstrated that in patients with pro-
gressive deterioration renal function (“creeping creati-
nine”) secondary to CAN, addition of MMF followed by
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withdrawal of CsA results in a significant improvement
of renal function without the risk of acute rejection [23].
These and other center-based studies [24] have demon-
strated that MMF is clinically useful for medium-term
treatment of CAN.
Little is known about whether MMF can also improve
histological lesions associated with CAN. However, two
MMF trials (American and tri-continental trials) ana-
lyzed sequential protocol biopsies from several centers.
The chronic allograft damage index (CADI) was eval-
uated in biopsies taken at baseline, 12 months, and 36
months [25]. The CADI increased from 1.3 at baseline
to 3.3 at 1 year and 4.1 at 3 years. Unfortunately, the
effect of immunosuppression on the progression of his-
tological lesions was not compared between treatment
with MMF and Aza/placebo. In the study by Nankiwell
that analyzed immunosuppression and interstitial fibrosis
[10], TAC and MMF were more potent than other condi-
tions in reducing early chronic interstitial fibrosis. MMF
was more protective than Aza in preventing a worsening
of the chronic interstitial fibrosis score. The beneficial ef-
fect of MMF on allograft fibrosis might result from the
reduction in tubular destruction by immunologic mecha-
nisms or by a positive effect on fibrogenesis.
SIROLIMUS
SRL, a mammalian TOR inhibitor, suppresses graft re-
jection by interfering with cytoplasmic, biochemical cas-
cades that transduce signals from the cell membrane to
the nucleus. In animal models of organ transplantation,
SRL exhibits potent anti-rejection activity and the abil-
ity to prolong allograft survival [26, 27]. Because SRL
does not inhibit calcineurin, SRL should lack the nephro-
toxic profile of calcineurin inhibitors. Preclinical studies
have also indicated that SRL has no deleterious effects
on renal function [27, 28], and that the combination of
SRL and MMF is particularly promising, because it sup-
presses transforming growth factor-beta and had no ef-
fect on glomerular filtration. SRL also inhibits growth
factor-stimulated smooth muscle cell proliferation and
migration [26] and reduces neointimal hyperplasia by
its inhibitory effect on arterial smooth muscle [29]. Ad-
ditionally, despite elevating serum lipid concentrations,
SRL inhibits atherosclerosis in experimental mouse mod-
els of atherogenesis [30].
Clinical studies have confirmed the success of SRL as
a prophylaxis for acute renal transplant rejection when
used concomitantly with existing therapies. Early studies
included a phase 2 trial [31] and two phase 3 trials that
compared an SRL-CsA combination with Aza [32] or
placebo [33] and demonstrated reduced acute rejection
rates. However, the phase 3 trials demonstrated that SRL
exacerbated the nephrotoxic effects of CsA.
Two early phase 2 studies directly compared the effects
of SRL and CsA in Europe [34–36]. Patients received ei-
ther CsA or SRL in combination therapy with either cor-
ticosteroids and Aza or corticosteroids and MMF. SRL
did not exhibit the nephrotoxic properties of CsA, and
renal function was enhanced after CsA-free, SRL-based
therapy. The 2-year data continued to show more favor-
able outcomes for risk factors such as hypertension and
renal function in response to SRL therapy than with CsA
therapy [36]. Although the benefits of decreased hyper-
tension and improved renal function were evident with
SRL therapy, the poor lipid profiles were a side effect that
had to be managed with increased use of lipid-lowering
therapy.
Flechner et al directly compared SRL and CsA and
reported improved outcomes by adding an induction
agent and reducing the doses of SRL to minimize side
effects [37]. Their randomized phase 2 trial used basil-
iximab as an antilymphocyte-induction agent, and SRL
or CsA in addition to MMF and steroids in primary re-
nal allograft recipients. The results showed comparable
outcomes for patient survival, graft survival, and biopsy-
confirmed acute rejection and significantly better renal
function in SRL-treated patients. Although higher than
at baseline, fasting lipid concentrations were similar in
both the SRL and CsA groups at all times studied in
the 1-year period. Subsequent analysis at 2 years demon-
strated that patients on SRL exhibited better renal func-
tion, lower prevalence of CAN (normal biopsies, 66% vs.
20.8%), and downregulated expression of genes linked to
the pathways of tissue injury–remodeling and immune or
inflammatory responses responsible for the progression
of CAN [38]. The authors concluded that this treatment
may provide an alternative to the natural history of CAN
with improved graft survival.
Because SRL exacerbated CsA nephrotoxicity in
phase 3 trials, a new phase 3 trial of early CsA withdrawal,
the Rapamune Maintenance Regimen (RMR) study, was
conducted [39]. The regimen comprised the administra-
tion of SRL (2 mg), CsA, and steroids after transplan-
tation, followed by randomization to CsA withdrawal 3
months with SRL through concentrations targeted at 20
ng/mL to 30 ng/mL (immunoassay) until month 12, and
15 ng/mL to 25 ng/mL thereafter. The results of this study
confirmed that CsA withdrawal provides the benefits of
improved renal function and lower blood pressure. At 12
months [40], both groups showed similar patient and graft
survival rates. Acute rejection rates were 4.2% and 9.8%
for SRL-CsA-steroid (ST) and SRL-ST, respectively
(P = 0.035).
Ruiz et al reported histological data at 1 year on 64
patients from Spain and Portugal enrolled in this trial,
and showed that the percentage of patients in whom
chronic lesions progressed was lower in the CsA elim-
ination group than in the SRL group [40]. Significant
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Table 1. Histological changes at 3 years in patients receiving sirolimus-based therapy after early CsA elimination
Engraftment 12 months 36 months
Score (mean ± SD) SRL+CsA SRL SRL+CsA SRL SRL+CsA SRL
CADI 1.26 ± 1.60 0.99 ± 0.92 3.74 ± 1.84 3.53 ± 1.66 4.70 ± 1.86a 3.20 ± 1.85a
Inflammation 0.11 ± 0.35 0.01 ± 0.06 0.59 ± 0.43a 0.82 ± 0.51a 0.64 ± 0.51b 0.50 ± 0.51b
Tubular atrophy 0.08 ± 0.27 0.08 ± 0.19 0.70 ± 0.42 0.56 ± 0.52 0.77 ± 0.50a,b 0.32 ± 0.41a,b
Intimal proliferation 0.10 ± 0.24 0.14 ± 0.38 0.46 ± 0.52 0.34 ± 0.39 0.67 ± 0.70 0.41 ± 0.52
Glomerular sclerosis 0.33 ± 0.41 0.23 ± 0.38 0.27 ± 0.54 0.18 ± 0.28 0.64 ± 0.57 0.37 ± 0.57
Mesangial matrix 0.27 ± 0.34 0.20 ± 0.27 0.47 ± 0.40 0.49 ± 0.36 0.78 ± 0.38 0.62 ± 0.48
Fibrosis 0.37 ± 0.52 0.33 ± 0.38 1.26 ± 0.63 1.13 ± 0.70 1.21 ± 0.53 0.99 ± 0.61
Abbreviations are: CsA, cyclosporine A; SD, standard deviation; SRL, sirolimus; CADI, chronic allograft damage index. Data from Mota, Am J Transplant 4:953–961,
2004.
aP < 0.05 between groups, analysis of covariance, change from engraftment.
bP < 0.05 between groups, analysis of covariance, change 12 to 36 months.
differences were observed in chronic interstitial fibrosis
(70% vs. 41%) and tubular lesions (70% vs. 48%), but
without differences in acute lesions indicative of subclini-
cal rejection. The prevalence of CAN and the severity and
incidence of new cases were lower in the SRL group. This
observation at 1 year suggests that the benefits should
continue in the long term [41].
A similarly designed study from Italy [42] evaluated
the impact of early CsA withdrawal on kidney graft and
structure at 1 year in patients receiving SRL-ST. Forty
consecutive renal transplant patients were treated with
steroids, CsA, and SRL (2 mg/day). After 3 months, pa-
tients were randomly assigned to receive the same ther-
apy or to withdraw CsA and continue with SRL-ST. All
patients underwent graft biopsy after reperfusion and 12
months after transplantation. Interestingly, CAN was di-
agnosed in 55% of all patients at 12 months, 64% in the
group treated with SRL-CsA-ST, and 36% in patients
treated with SRL-ST. CAN lesions were scored as moder-
ate to severe in 90% of patients treated with SRL-CsA-ST
compared with 32% in patients with SRL-ST. Notably, a
vascular score ≥2 was present in 90% in the group treated
with SRL-CsA-ST and in 38% of patients treated with
SRL-ST. In addition, at 1 year, renal function was better
in patients treated with SRL-ST. These results suggest
that early elimination of CsA allows a significant reduc-
tion of chronic histological damage, particularly vascular
injury.
At 24 months in the RMR study [42], the two groups
did not differ significantly on patient survival, graft sur-
vival, acute rejection after randomization, and discontin-
uations. Serum creatinine concentration was significantly
lower in the CsA withdrawal group than in the SRL group
(167 lmol/L vs. 128 lmol/L, P < 0.001). The slope of 1/cre-
atinineand systolic blood pressure was also significantly
lower (141 mm Hg vs. 134 mm Hg, P < 0.001) in the
CsA-withdrawal group. High-density lipoprotein choles-
terol concentration was significantly higher in the SRL-
ST group, whereas the concentrations of total cholesterol,
low-density lipoprotein cholesterol, and triglyceride did
not differ significantly between the two groups.
Analysis of the RMR data at 36 months [43] showed a
continuing beneficial trend in graft survival in the SRL-
ST group. Acute rejection rates from randomization to
month 36 did not differ significantly between the SRL-ST
and SRL-CsA-ST groups, although serum creatinine con-
centration was significantly lower, and overall renal func-
tion improved or remained stable in the SRL-ST group.
Blood lipid measures and cumulative use of statins were
similar between the groups.
Histological data at 3 years was available from 484
biopsies performed at engraftment at 12 and 36 months
[44]. Two pathologists blindly evaluated all biopsies to
obtain the CADI scores. At 36 months, among 63 pa-
tients with serial biopsies, the SRL-ST group had a sig-
nificantly lower main CADI score (4.7 vs. 3.2, P = 0.003)
and mean tubular atrophy score (0.77 vs. 0.32, P < 0.001).
All six components of the CADI score (inflammation,
tubular atrophy, intimal proliferation, glomerular scle-
rosis, mesangial matrix, and fibrosis) were numerically
lower in the SRL-ST group. The inflammation and tubu-
lar atrophy scores decreased significantly between 12 and
36 months in the SRL-ST group (0.82 to 0.50, and 0.56
to 0.32, respectively) (Table 1). The calculated GFR was
significantly higher in SRL-ST patients (68.2 mL/min vs.
54.8 mL/min). This study clearly demonstrated that with-
drawing CsA from the SRL-CsA-ST regimen results in
improved renal function and renal histology.
At 48 months in the RMR study [45], graft survival
censored for loss to follow-up was significantly better af-
ter CsA withdrawal, either when including death with
a functioning graft as an event (84.1% vs. 91.5%, P =
0.024, Fig. 1) or when excluding it (90.5% vs. 96.1%,
P = 0.025). The incidence of death (7.9% vs. 4.7%) or
biopsy-proven acute rejection after randomization (7.0%
vs. 10.2%) did not differ significantly between the SRL-
CsA-ST and SRL-ST groups. As shown in Figure 2, the
calculated GFR, which included values from discontin-
ued patients and set GFR to 0 for functional graft loss, was
significantly higher (43.8 mL/min vs. 58.3 mL/min, P <
0.001) in the CsA withdrawal group. Mean arterial blood
pressure (101.0 mm Hg vs. 97.6 mm Hg, P = 0.046) was
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Fig. 1. Graft survival, censored for loss to follow-up, in the RMR study
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ney Int 67:S69–S73, 2005).
lower in the SRL-ST group despite significantly less anti-
hypertensive therapy (P < 0.001). The cumulative 4-year
data demonstrated superior outcomes for renal function,
stabilized lipid values, and the ongoing benefit of lower
blood pressure in patients receiving SRL-ST. This was the
first trial in the new immunosuppressive era to demon-
strate that the protocol based on SRL and eliminating
CsA 3 months after transplantation leads to significantly
better graft survival, renal function, and renal histology
than the CsA and SRL protocol.
Others have explored the conversion from antical-
cineurin inhibitors to SRL in patients with chronic al-
lograft dysfunction [46, 47]. Diekmann et al showed that
proteinuria <800 mg/day at conversion was the only in-
dependent predictor for a positive outcome in conver-
sion from anticalcineurin drugs to SRL in patients with
chronic allograft dysfunction [46]. These limited data sug-
gest that early conversion to SRL in patients with mod-
erate insufficiency could be useful for treating chronic
allograft dysfunction [47].
The antiproteinuric and antiproliferative actions of
angiotensin-converting enzyme inhibitors or angiotensin
II receptor antagonists might be useful in combination
with MMF or SRL in patients with CAN. A rat model
of renal allograft showed that losartan dramatically re-
duces nephrotic proteinuria [48], diminishes transform-
ing growth factor-beta in patients with CAN [49], and,
when combined with MMF, fully protects against chronic
rejection [50]. A prospective study exploring the value of
including losartan in the ST-TAC-MMF protocol to pre-
vent CAN is ongoing. The role of statins as renoprotective
drugs in CAN remains to be determined [4].
CONCLUSION
The introduction of the non-nephrotoxic drugs MMF
and mammalian TOR inhibitors may provide new im-
munosuppressive strategies to improve long-term results
after renal transplantation. MMF decreases the risk for
developing chronic allograft failure, is useful for treating
established CAN, and has a beneficial effect on allograft
fibrosis.
SRL as a basic immunosuppressive agent associated
with MMF, steroids, and basiliximab may offer better
renal function, reduce the prevalence of CAN, and down-
regulate expression of genes responsible for the progres-
sion of CAN compared with CsA treatment. SRL may
also permit an early elimination of CsA from ST-CsA-
SRL regimes and improve renal function and renal his-
tology without increasing the risk of rejection. Notably,
this approach increased graft survival at 4 years. An ex-
tension of other trials with SRL to assess the long-term
safety of SRL with CsA and to compare this with SRL
treatment without CsA showed that patients on SRL-
based therapy exhibited long-term improvement in renal
function with no increase risk of late acute rejection [51].
Because TAC is the most frequently used antical-
cineurin drug, further multicenter studies are needed to
determine whether SRL-based treatment produces sim-
ilar results to those of TAC-based immunosuppression,
and to compare TAC elimination from ST-TAC-SRL with
a regimen that maintains TAC. A pilot Spanish study
showed encouraging results, with better function in pa-
tients when TAC was eliminated from the ST-TAC-SRL
regimen [52, 53], although no histological data are avail-
able. Whether these protocols based on SRL can also be
extended to high-risk patients is currently unknown. Fi-
nally, although caution is needed, it can be speculated that
the use of non-nephrotoxic immunosuppression might
change the natural history of CAN.
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